Literature DB >> 16467204

Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis.

Binghui Li1, Nan Jia, Reuben Kapur, Kristin T Chun.   

Abstract

As erythroid progenitors differentiate into precursors and finally mature red blood cells, lineage-specific genes are induced, and proliferation declines until cell cycle exit. Cul4A encodes a core subunit of a ubiquitin ligase that targets proteins for ubiquitin-mediated degradation, and Cul4A-haploinsufficient mice display hematopoietic dysregulation with fewer multipotential and erythroid-committed progenitors. In this study, stress induced by 5-fluorouracil or phenylhydrazine revealed a delay in the recovery of erythroid progenitors, early precursors, and normal hematocrits in Cul4A(+/-) mice. Conversely, overexpression of Cul4A in a growth factor-dependent, proerythroblast cell line increased proliferation and the proportion of cells in S phase. When these proerythroblasts were induced to terminally differentiate, endogenous Cul4A protein expression declined 3.6-fold. Its enforced expression interfered with erythrocyte maturation and cell cycle exit and, instead, promoted proliferation. Furthermore, p27 normally accumulates during erythroid terminal differentiation, but Cul4A-enforced expression destabilized p27 and attenuated its accumulation. Cul4A and p27 proteins coimmunoprecipitate, indicating that a Cul4A ubiquitin ligase targets p27 for degradation. These findings indicate that a Cul4A ubiquitin ligase positively regulates proliferation by targeting p27 for degradation and that Cul4A down-regulation during terminal erythroid differentiation allows p27 to accumulate and signal cell cycle exit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467204      PMCID: PMC1895787          DOI: 10.1182/blood-2005-08-3349

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Proteolysis and the cell cycle: with this RING I do thee destroy.

Authors:  M Tyers; P Jorgensen
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

2.  Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.

Authors:  D M Koepp; L K Schaefer; X Ye; K Keyomarsi; C Chu; J W Harper; S J Elledge
Journal:  Science       Date:  2001-08-30       Impact factor: 47.728

3.  p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells.

Authors:  H Sutterlüty; E Chatelain; A Marti; C Wirbelauer; M Senften; U Müller; W Krek
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

4.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

5.  Covalent modification of all members of human cullin family proteins by NEDD8.

Authors:  T Hori; F Osaka; T Chiba; C Miyamoto; K Okabayashi; N Shimbara; S Kato; K Tanaka
Journal:  Oncogene       Date:  1999-11-18       Impact factor: 9.867

Review 6.  Proteasome inhibition as a novel therapeutic target in human cancer.

Authors:  S Vincent Rajkumar; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

7.  Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.

Authors:  W Yang; J Shen; M Wu; M Arsura; M FitzGerald; Z Suldan; D W Kim; C S Hofmann; S Pianetti; R Romieu-Mourez; L P Freedman; G E Sonenshein
Journal:  Oncogene       Date:  2001-03-29       Impact factor: 9.867

8.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication.

Authors:  K Nakayama; H Nagahama; Y A Minamishima; M Matsumoto; I Nakamichi; K Kitagawa; M Shirane; R Tsunematsu; T Tsukiyama; N Ishida; M Kitagawa; K Nakayama; S Hatakeyama
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

9.  Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.

Authors:  H Strohmaier; C H Spruck; P Kaiser; K A Won; O Sangfelt; S I Reed
Journal:  Nature       Date:  2001-09-20       Impact factor: 49.962

10.  Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines.

Authors:  K H Moberg; D W Bell; D C Wahrer; D A Haber; I K Hariharan
Journal:  Nature       Date:  2001-09-20       Impact factor: 49.962

View more
  56 in total

1.  Insights into hemoglobin assembly through in vivo mutagenesis of α-hemoglobin stabilizing protein.

Authors:  Eugene Khandros; Todd L Mollan; Xiang Yu; Xiaomei Wang; Yu Yao; Janine D'Souza; David A Gell; John S Olson; Mitchell J Weiss
Journal:  J Biol Chem       Date:  2012-01-27       Impact factor: 5.157

2.  Cul4A is required for hematopoietic stem-cell engraftment and self-renewal.

Authors:  Binghui Li; Nan Jia; David L Waning; Feng-Chun Yang; Laura S Haneline; Kristin T Chun
Journal:  Blood       Date:  2007-07-06       Impact factor: 22.113

Review 3.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

4.  Suppression of autophagy during mitosis via CUL4-RING ubiquitin ligases-mediated WIPI2 polyubiquitination and proteasomal degradation.

Authors:  Guang Lu; Juan Yi; Andrea Gubas; Ya-Ting Wang; Yihua Wu; Yi Ren; Man Wu; Yin Shi; Chenxi Ouyang; Hayden Weng Siong Tan; Tianru Wang; Liming Wang; Nai-Di Yang; Shuo Deng; Dajing Xia; Ruey-Hwa Chen; Sharon A Tooze; Han-Ming Shen
Journal:  Autophagy       Date:  2019-03-30       Impact factor: 16.016

5.  Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer.

Authors:  Shancheng Ren; Chuanliang Xu; Zilian Cui; Yongwei Yu; Weidong Xu; Fubo Wang; Ji Lu; Min Wei; Xin Lu; Xu Gao; You Liang; Jian-Hua Mao; Yinghao Sun
Journal:  J Mol Med (Berl)       Date:  2012-03-16       Impact factor: 4.599

6.  Clinical significance of CUL4A in human prostate cancer.

Authors:  Gang Liu; Zengjun Zhu; Fang Lang; Bao Li; Dianjun Gao
Journal:  Tumour Biol       Date:  2015-06-03

7.  Knockdown of CUL4B inhibits proliferation and promotes apoptosis of colorectal cancer cells through suppressing the Wnt/β-catenin signaling pathway.

Authors:  Baoji Song; Hongjie Zhan; Quan Bian; Jiarui Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors.

Authors:  Gustavo A Miranda-Carboni; Susan A Krum; Kathleen Yee; Miguel Nava; Qiming E Deng; Shehla Pervin; Alicia Collado-Hidalgo; Zoran Galic; Jerome A Zack; Keiko Nakayama; Keiichi I Nakayama; Timothy F Lane
Journal:  Genes Dev       Date:  2008-11-15       Impact factor: 11.361

9.  EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.

Authors:  Silverio Perrotta; Valeria Cucciolla; Marcella Ferraro; Luisa Ronzoni; Annunziata Tramontano; Francesca Rossi; Anna Chiara Scudieri; Adriana Borriello; Domenico Roberti; Bruno Nobili; Maria Domenica Cappellini; Adriana Oliva; Giovanni Amendola; Anna Rita Migliaccio; Patrizia Mancuso; Ines Martin-Padura; Francesco Bertolini; Donghoon Yoon; Josef T Prchal; Fulvio Della Ragione
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

10.  Proliferation defects and genome instability in cells lacking Cul4A.

Authors:  D Kopanja; T Stoyanova; M N Okur; E Huang; S Bagchi; P Raychaudhuri
Journal:  Oncogene       Date:  2009-05-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.